Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 361-366

  Saleh, El Awady ^a   Lithy, R ^a   Morshed, M ^a   Khafagy, W ^a   Abd, Monem H ^a   Waleed, Omar ^a   Badr, S ^a   Fekry, A ^a   El, Nakeeb A ^a   Ghazy, H ^a   El, Yamany M ^a   Metwally, T ^a   Mohamed, El Arman ^a   Mohamed, Farid ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Basal CEA; Colorectal cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CHEMOLUMINESCENCE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; CARCINOEMBRYONIC ANTIGEN; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUMINESCENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 67649209944     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Figueredo A, Rumble R, Maroun J, et al: Follow up of patients with curatively resected colorectal cancer a practicalguideline.http://www. biomedcentral.com.2003;/1471-2407/3/26
2. Gold P and Freedman SO: Demonstration of tumor specific antigens in human colonic carcinoma by immunologi-cal tolerance and absorption techniques. J Exp Med.1965; 121: 439-462.
3. Duffy M:Carcinoemberyonic antigen as a marker for colorectal cancer is it clinically useful. Clinical Chem-istry2001; 47: 624-30.
4. Forones NM and Tanaka M: CEA & CA19-9 as prognostic indexes in colorectal cancer.Hepatogastroenterolo-gy.1999; 46: 905-908.
5. Carriquiry LA and Pineyro A : Should carcinoembryon-ic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum.1999; 42: 7, 921-929.
6. Boczynska D, Wietrzyk J, Made J, et al: The tumoro-genic potential of human CX-1colon adenocarcinoma depends on carcinoembryonic antigen expression. Cellular &Molecular Biology Letters.2003;8:471-486. http://www.cmbl.org.pl
7. Bensen AB, Desch CE, Flynn P J, et al: Update of American Society of Clinical Colorectal Cancer Surveillance Guidelines. J Cl Oncology.2000;18: 3586-8.
8. Oberg AN, Lindmark GE, Israelsson AC, et al: Detection of occult tumor cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CD20 mRNAS. Int J Cancer.2000; 111(1): 101-10.
9. Forslund A, Engaras B, LonRoth C, et al: Prediction of postoperative survival by preoperative concentrations of anti-P53 compared to CEA, CA50, CA242 and conventional blood tests in patients with colorectal cancer. International J of Oncology.2002; 20: 1013-1018.
10. Harrison LE, Guillem JG, Paty P, et al: Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg.1997; 185(1): 55-9.
11. Marchena J, Acosta MA, Cruz F, et al: Use of preoperativelevels of CEA inpatientswith colorectal cancer. Hepatogastroenter-ology.2003; 50: 1017-1020.
12. NorthoverJ: Which type of follow up. Hepatogastroenter-ology. 2000; 37: 335-336.
13. Begent R: The value of carcinoemberyonic antigen measurement in clinical practice. Ann Clin Biochem.1972; 21: 231-235.
14. Dukes'CE: The classification of cancer of rectum. JPathol Bacteriol.1932; 35: 323-332.
15. Simon R: Use of regression models: Statistical aspects. In: Buyse ME. Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials: Methods and Practice. Oxford, England, Oxford University Press. 1984; PP: 444-466.
16. Bombski G, Gasiorowska A, Orszulak-Michalak D, et al: Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection. Int J Colorectal Dis.2002; 18(2): 148-52.
17. Engaras B, Kewenter J, Nilssson O, et al: CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease. Eur J Surg Oncol.2001; 27(1): 43-8.
18. Grotowski M: Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer. Pol Merkuriusz Lek.2002; 12(67): 77-80.
19. Turoldo A, Balani A, Scaramucci M, et al: Prognostic importance of preoperative CEA in patients with colorectal cancer. Chir Ital.2002; 54(4): 469-76.
20. Chapman MA, Buckley D, Henson DB, et al: Preoperative carcinoembryonic antigen is related to tumor stage and long term survival in colorectal cancer. Br J Cancer. 1998; 78(10): 1346-9.
21. Scott NA, Wieand HS, Moertel CG, et al: Colorectal cancer: Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg. 1987; 112: 1375-9.
22. Allende T, Garcia Muniz JL, Vizoso F, et al: Preoperative serum levels of the carcinocmbryonic antigen (CEA) and prognosis in colorectal cancer. Rev Esp Med Nucl.2001; 20(5): 358-64.
23. Bel Hadj Hmida Y, Tahri N, Sellami A, et al: Sensitivity, specificity and prognostic value of CEA in colorectal cancer: results of a Tunisian series and literature review. Tunis Med.2001; 79(8-9): 434-40.
24. Park YJ, Park KJ, Park JG, et al: Prognostic factors in 2230 Korean colorectal cancer patients. Analysis of consecutively operated cases.World J of Surgery.1999; 22: 721-726.
25. Grotowski M, Maruszynski M, Piechota W: Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients. Pol Merkuriusz Lek.2001; 11(66): 476-9.
26. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Sten-man et al: Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Can-cer.2002; 101(6): 545-8.
27. Celen O, Kahraman I, Yildirim E, et al: Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variable in colorectal cancer patients. Neoplasma.2004; 51(4): 293-9.
28. Bhatavdekar JM, Patel PD, Chikhlikar PR, et al: Molecular markers are predictors in patients with Dukes' B and Dukes' C eolorectal carcinoma. Dis Col Rect; PP.2001: 523-533.
29. Moertel CG, O'Fallon JR, Go VLW, et al: The preopera tive carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer.1986; 58: 603-10.
30. Carpelan-Holmstrom M, Haglund C, Lundin J, et al: Pro-operative levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer.1996; 32A: 1156-61.
31. Wanebo JH, Rao B, Pinsky CM, et al: Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med.1987; 299: 448-51.
32. Anonymous: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1996; 14: 2843-77.
33. Ishida H, Miwa H, Tatsuta M, et al: Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett.2004; 207(1): 109-15.
34. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al: American joint committee on cancer prognostic factors. Factors conference consensus colorectal working group.Cancer.2000; 88: 1739-1757.
35. Grem J: The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol.l997;9:380-7.
36. Figueredo A, Rumble RB, Maroun J, et al: Follow up of patients with curatively resected colorectal cancer. A practice guideline, http://www.biomedcentral.com.2005;/1471-2407-3/26.
37. Wiratkapun S, Kramer M, Seow-Choen F, et al: High preoperative carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of 5-years study. Dis Colon Rectum.2001; 44(2): 231-235.
38. Pietra N, Sarli L, Costi R, et al: Role of follow-up in management of local recurrence of colorectal cancer, a prospective randomized study. Dis Colon Rectum.1998; 41: 1127-33.
39. Goldie HJ: Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol.1997; 14: 1-7.
40. Ian Chau, Mark J Allen, David Cunningham, et al: The value of routine serum carcinoembryonic antigen measurement and computed tomography in the Surveillance of patients after adjuvant chemotherapy for colorectal cancer. Journal of Clinical Oncology.2004; 22(8): 1420-1429.